GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-170783 | Pharmaceuticals and Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET
7.1 GLOBAL GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Novartis
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Pfizer
16.3 Fresenius Kabi
16.4 Teva Pharmaceuticals
16.5 Sun Pharma
16.6 Hutchison China MediTech Limited
16.7 Exelixis Inc.
16.8 Tarveda Therapeutics
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeChemotherapy
Peptide-Receptor Radionuclide Therapy
By Application
Hospitals
Clinics
Ambulatory Surgical Centers
Companies
Novartis
Pfizer
Fresenius Kabi
Teva Pharmaceuticals
Sun Pharma
Hutchison China MediTech Limited
Exelixis Inc.
Tarveda Therapeutics
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.